661 reports of this reaction
2.7% of all VALGANCICLOVIR HYDROCHLORIDE POWDER, reports
#5 most reported adverse reaction
LEUKOPENIA is the #5 most commonly reported adverse reaction for VALGANCICLOVIR HYDROCHLORIDE POWDER,, manufactured by Ajanta Pharma USA Inc.. There are 661 FDA adverse event reports linking VALGANCICLOVIR HYDROCHLORIDE POWDER, to LEUKOPENIA. This represents approximately 2.7% of all 24,571 adverse event reports for this drug.
Patients taking VALGANCICLOVIR HYDROCHLORIDE POWDER, who experience leukopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LEUKOPENIA is a less commonly reported adverse event for VALGANCICLOVIR HYDROCHLORIDE POWDER,, but still significant enough to appear in the safety profile.
In addition to leukopenia, the following adverse reactions have been reported for VALGANCICLOVIR HYDROCHLORIDE POWDER,:
The following drugs have also been linked to leukopenia in FDA adverse event reports:
LEUKOPENIA has been reported as an adverse event in 661 FDA reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,. This does not prove causation, but indicates an association observed in post-market surveillance data.
LEUKOPENIA accounts for approximately 2.7% of all adverse event reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,, making it a notable side effect.
If you experience leukopenia while taking VALGANCICLOVIR HYDROCHLORIDE POWDER,, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.